New Real-World DOR Data for JELMYTO Reports 68% RFS at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
“We are excited by the three-year results showing the durability of JELMYTO in treating low-grade upper tract urothelial cancer, with 68% of patients remaining recurrence-free,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “These findings underscore the promising long-term potential of JELMYTO in managing this challenging disease. We are committed to improving the lives of patients with urothelial cancer and advancing our mission to deliver breakthrough therapies that transform the standard of care for patients with complex urological conditions.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.